TIDMVAL
RNS Number : 8714B
ValiRx PLC
07 June 2023
ValiRx PLC
("ValiRx" or the "Company")
Expanded Evaluation agreement with University of Barcelona
London, UK - ValiRx Plc (AIM: VAL), a life science company
focusing on early-stage cancer therapeutics and women's health, is
today pleased to announce that the evaluation agreement announced
on 14 February 2022 from Barcelona University has been expanded to
a broader collaboration including additional molecules targeting
KRAS (Kirsten RAt Sarcoma) as possible drugs for treating
cancer.
Under the previous agreement, ValiRx had been conducting a range
of experiments on the initial project from Barcelona University
over a period of twelve months. A lead series of peptidomimetic
therapeutic candidates was assessed initially in silico, with the
top four molecules selected for synthesis and in vitro testing.
These cell-based in vitro studies investigated the activity of the
four molecules against pancreatic cancer, uterine sarcoma and
ovarian cancer cells. Three of the four molecules selected
demonstrated good activity and one of them was then selected for
further study in vivo.
Whilst the in vivo study did not achieve the desired level of
anti-cancer activity, it demonstrated no adverse toxicity leading
to the conclusion that further research around this molecular
series would be beneficial.
The University of Barcelona has an active research group working
in this area and has been awarded a grant to further study the
effects of the same lead series. ValiRx has entered into an
expansion of the initial evaluation agreement ("Expanded Evaluation
Agreement") to continue to work alongside the recently funded
Barcelona research team to build a broader understanding of the
biological activity of the drug candidates.
The Expanded Evaluation Agreement includes research on an
additional series of molecules for a different, yet equally novel,
binding pocket of KRAS which are within the University of
Barcelona's research program; and the ability to consider further
compounds that may be developed at the University of Barcelona
under the format this agreement.
The Expanded Evaluation Agreement is scheduled to be active for
up to four years, with the potential to extend by a further four
years, with each project being subject to a standard set of legal
conditions, and each lead series undergoing a separate evaluation
process. Each evaluation process is expected to last up to 12
months, with success potentially leading to the set-up of a ValiRx
subsidiary to further progress the project.
Dr Suzy Dilly, CEO of ValiRx commented: "We are delighted to be
able to provide a letter of industrial support for the grant
application by the University of Barcelona and we very much look
forward to reviewing the additional data generated by the team. The
capability of this team in generating leads for assessment is truly
impressive, and we're pleased that we have set up this broader
framework to allow us to assess new molecules efficiently if they
emerge as suitable candidates for further development."
University of Barcelona research group's Principal Investigator
commented: " We appreciate the work conducted by ValiRx to expand
on the evaluation agreement with more of our projects giving us an
opportunity to advance our research in such an important area of
science. The support ValiRx brings us is extremely valuable for our
research and we anticipate the complimentary experiments and data
will reinforce our projects."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 as it forms part of
UK Domestic Law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR"). The Directors of the Company take responsibility
for this announcement.
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com
Dr Suzanne Dilly, CEO Suzanne.Dilly@valirx.com
V Formation (Public Relations) +44 (0) 115 787 0206
www.vformation.biz
Lucy Wharton - Senior PR Executive
Sue Carr - Director lucy@vformation.biz
sue@vformation.biz
--------------------------
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray/Jo Turner/Ludovico Lazzaretti
--------------------------
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397
8900
Dale Bellis/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate
Finance)
--------------------------
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3657
James Pope / Andy Thacker 0050
--------------------------
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer
therapeutics and women's health, accelerating the translation of
innovative science into impactful medicines to improve patient
lives.
ValiRx provides the scientific, financial, and commercial
framework for enabling rapid translation of innovative science into
clinical development.
Using its extensive and proven experience in research and drug
development, the team at ValiRx selects and incubates promising
novel drug candidates and guides them through an optimised process
of development, from pre-clinical studies to clinic and
investor-ready assets.
ValiRx connects diverse disciplines across scientific,
technical, and commercial domains, with the aim of achieving a more
streamlined, less costly, drug development process. The team works
closely with carefully selected collaborators and leverages the
combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or
partnered with investors through ValiRx subsidiary companies for
further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in
October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
About University of Barcelona
The University of Barcelona ("UB") is the largest public
university in Catalonia and one of the most prestigious higher
education institutions in Spain. According to the rankings, it is
the most innovative university in Spain in 2019. The UB is a member
of the League of European Research Universities ("LERU"), an
association that gathers the most important twenty-three research
university centres of the continent. Focused on academic
excellence, the UB is committed to provide the next generation of
-professionals, researchers, entrepreneurs, leaders with the skills
to carry out new research.
Technology transfer
The technology transfer and innovation unit of the University of
Barcelona ("UB") is the Bosch i Gimpera Foundation ("FBG"). The FBG
is responsible for transferring the results of the research carried
out at the UB to society through the creation of spin-offs, patent
licensing, and contracts with companies and institutions, thus
contributing to the competitiveness of the business framework and
the improvement of social welfare. In 2021, UB developed 564
projects and generated EUR 24.31 million in contractual revenue.
The UB has 132 transfer patents and 22 active spin-offs. The FBG
works towards the Sustainable Development Goals ("SDGs") through
transfer activities that are in-line with the 17 SDGs.
Cautionary statement
Certain statements made in this announcement are forward-looking
statements. Such statements are based on current expectations and
assumptions and are subject to a number of risks and uncertainties
that could cause actual events or results to differ materially from
any expected future events or results expressed or implied in these
forward-looking statements. Persons receiving this announcement
should not place undue reliance on forward-looking statements.
Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or
revise any forward-looking statements, whether as a result of new
information, future developments or otherwise.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRGZGGVLVFGFZM
(END) Dow Jones Newswires
June 07, 2023 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De May 2023 a May 2024